{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:19:40Z","timestamp":1788380380267,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":981,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100010002","name":"Ministry of Education","doi-asserted-by":"publisher","award":["24591386"],"award-info":[{"award-number":["24591386"]}],"id":[{"id":"10.13039\/100010002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010002","name":"Ministry of Education","doi-asserted-by":"publisher","award":["15K09470"],"award-info":[{"award-number":["15K09470"]}],"id":[{"id":"10.13039\/100010002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.exphem.2019.09.023","type":"journal-article","created":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T11:16:57Z","timestamp":1569323817000},"page":"46-55.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Glycolytic enzyme hexokinase II is a putative therapeutic target in B-cell malignant lymphoma"],"prefix":"10.1016","volume":"78","author":[{"given":"Kei","family":"Nakajima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Koshiisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Mitsumori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Kirito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2019.09.023_bib0001","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1038\/sj.onc.1209603","article-title":"Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria","volume":"25","author":"Mathupala","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2019.09.023_bib0002","article-title":"Role of hypoxia in diffuse large B-cell lymphoma: metabolic repression and selective translation of HK2 facilitates development of DLBCL","volume":"8","author":"Bhalla","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.exphem.2019.09.023_bib0003","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.18632\/oncotarget.23425","article-title":"Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development","volume":"9","author":"Gu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.exphem.2019.09.023_bib0004","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.exphem.2010.08.007","article-title":"NF-kappaB mediates aberrant activation of HIF-1 in malignant lymphoma","volume":"38","author":"Qiao","year":"2010","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2019.09.023_bib0005","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.1128\/MCB.00440-07","article-title":"Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1","volume":"27","author":"Kim","year":"2007","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.exphem.2019.09.023_bib0006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136142","article-title":"Different mechanisms of regulation of the Warburg effect in lymphoblastoid and Burkitt lymphoma cells","volume":"10","author":"Mushtaq","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2019.09.023_bib0007","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.phrs.2016.01.001","article-title":"Cisplatin resistance and opportunities for precision medicine","volume":"106","author":"Amable","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.exphem.2019.09.023_bib0008","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.canlet.2016.01.009","article-title":"Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism","volume":"373","author":"Ai","year":"2016","journal-title":"Cancer Lett"},{"key":"10.1016\/j.exphem.2019.09.023_bib0009","first-page":"801","article-title":"Hypoxia exposure induced cisplatin resistance partially via activating p53 and hypoxia inducible factor-1\u03b1 in non-small cell lung cancer A549 cells","volume":"16","author":"Guo","year":"2018","journal-title":"Oncol Lett"},{"key":"10.1016\/j.exphem.2019.09.023_bib0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.biocel.2017.12.010","article-title":"Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy","volume":"95","author":"Zhang","year":"2018","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.exphem.2019.09.023_bib0011","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.4161\/cc.8.20.9853","article-title":"Hexokinase II detachment from the mitochondria potentiates cisplatin induced cytotoxicity through a caspase-2 dependent mechanism","volume":"8","author":"Shulga","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.exphem.2019.09.023_bib0012","doi-asserted-by":"crossref","first-page":"16507","DOI":"10.1074\/jbc.272.26.16507","article-title":"A distinct function of STAT proteins in erythropoietin signal transduction","volume":"272","author":"Kirito","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2019.09.023_bib0013","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nature07968","article-title":"Mutations of multiple genes cause deregulation of NF-B in diffuse large B-cell lymphoma","volume":"459","author":"Compagno","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2019.09.023_bib0014","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1600-0609.1999.tb01766.x","article-title":"Somatic mutations and intraclonal variations in the rearranged Vk genes of B-non-Hodgkin's lymphoma cell lines","volume":"63","author":"Gabay","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.exphem.2019.09.023_bib0015","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/bjh.12324","article-title":"Downregulation of glutathione transferase \u03c0 sensitizes lymphoma\/leukaemia cells to platinum-based chemotherapy","volume":"162","author":"Chen","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2019.09.023_bib0016","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1158\/1078-0432.CCR-07-4306","article-title":"Combination strategy targeting the hypoxia inducible factor-1\u03b1 with mammalian target of rapamycin and histone deacetylase inhibitors","volume":"14","author":"Verheul","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2019.09.023_bib0017","article-title":"Histone deacetylase inhibitors: the epigenetic therapeutics that repress hypoxia-inducible factors","volume":"2011","author":"Chen","year":"2011","journal-title":"J Biomed Biotechnol"},{"key":"10.1016\/j.exphem.2019.09.023_bib0018","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.nucmedbio.2008.11.009","article-title":"Expressions of glucose transporter types 1 and 3 and hexokinase-II in diffuse large B-cell lymphoma and other B-cell non-Hodgkin's lymphomas","volume":"36","author":"Shim","year":"2009","journal-title":"Nuclear Med Biol"},{"key":"10.1016\/j.exphem.2019.09.023_bib0019","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12967-017-1258-9","article-title":"Regulation of glucose uptake in lymphoma cell lines by c-MYC- and PI3K-dependent signaling pathways and impact of glycolytic pathways on cell viability","volume":"15","author":"Broecker-Preuss","year":"2017","journal-title":"J Transl Med"},{"key":"10.1016\/j.exphem.2019.09.023_bib0020","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/bjh.15412","article-title":"How I manage patients with relapsed\/refractory diffuse large B cell lymphoma","volume":"182","author":"Gisselbrecht","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2019.09.023_bib0021","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.bbcan.2010.07.004","article-title":"Cisplatin resistance: preclinical findings and clinical implications","volume":"1806","author":"K\u00f6berle","year":"2010","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.exphem.2019.09.023_bib0022","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1158\/1535-7163.MCT-05-0491","article-title":"DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance","volume":"5","author":"Lin","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.exphem.2019.09.023_bib0023","doi-asserted-by":"crossref","first-page":"8921","DOI":"10.18632\/oncotarget.13475","article-title":"The role of p53 in cancer drug resistance and targeted chemotherapy","volume":"8","author":"Hientz","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.exphem.2019.09.023_bib0024","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1002\/j.1460-2075.1991.tb07837.x","article-title":"p53 is frequently mutated in Burkitt's lymphoma cell lines","volume":"10","author":"Farrell","year":"1991","journal-title":"EMBO J"},{"key":"10.1016\/j.exphem.2019.09.023_bib0025","doi-asserted-by":"crossref","first-page":"5413","DOI":"10.1073\/pnas.88.12.5413","article-title":"p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia","volume":"88","author":"Gaidano","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.exphem.2019.09.023_bib0026","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/bjh.13849","article-title":"The presence of genomic imbalances is associated with poor outcome in patients with Burkitt lymphoma treated with dose-intensive chemotherapy including rituximab","volume":"172","author":"Forero-Castro","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2019.09.023_bib0027","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.celrep.2014.07.053","article-title":"Hexokinase 2-mediated Warburg effect is required for PTEN- and p53-deficiency-driven prostate cancer growth","volume":"8","author":"Wang","year":"2014","journal-title":"Cell Rep"},{"key":"10.1016\/j.exphem.2019.09.023_bib0028","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1476-4598-14-4","article-title":"Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1\u03b1 destabilization","volume":"14","author":"Fischer","year":"2015","journal-title":"Mol Cancer"},{"key":"10.1016\/j.exphem.2019.09.023_bib0029","doi-asserted-by":"crossref","first-page":"e90196","DOI":"10.1172\/jci.insight.90196","article-title":"Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations","volume":"2","author":"Mondello","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.exphem.2019.09.023_bib0030","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1182\/blood-2016-02-699520","article-title":"Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma","volume":"128","author":"Assouline","year":"2016","journal-title":"Blood"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X19310227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X19310227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:34:32Z","timestamp":1759566872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X19310227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":30,"alternative-id":["S0301472X19310227"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2019.09.023","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glycolytic enzyme hexokinase II is a putative therapeutic target in B-cell malignant lymphoma","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2019.09.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 ISEH -- Society for Hematology and Stem Cells. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}